IP Library Granted Patent US 8,465,740
Granted Patent B2
US 8,465,740 · App. 13/326,792 · Granted Jun 18, 2013

Regulatory T cell mediator proteins and uses thereof

Inventors: Randolph J. Noelle (Plainfield, NH); Li-Fan Lu (Seattle, WA); Sergio Quezada (New York, NY); David Gondek (Brookline, MA)
Assignee: Trustees of Dartmouth College
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,465,740
App. No.
13/326,792
Granted
Jun 18, 2013
Kind
B2
Abstract

The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated T reg -sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed.

Claims (10)

1. A method of promoting T cell immunity against a viral infectious agent comprising administering an effective amount of an anti-PD-L3 antibody or antibody fragment that specifically binds to the extracellular region of the human PD-L3 protein having the sequence in SEQ ID NO:4, wherein said anti-PD-L3 antibody or antibody fragment antagonizes the immunosuppressive effect of PD-L3 on T cell immunity in vivo, and thereby potentiates T cell immune response against the viral infectious agent.

2. The method of claim 1 , wherein the anti-PD-L3 antibody or antibody fragment antagonizes one or more of the following effects of PD-L3 on T cell function in vivo:

(1) suppression of T cell activation or differentiation;

(2) suppression of CD4+T cell proliferation,

(3) suppression of CD8+T cell proliferation and

(4) suppression of cytokine production by T cells.

3. The method of claim 1 , wherein the antibody or antibody fragment is a chimeric, human or humanized antibody or fragment thereof.

4. The method of claim 1 , wherein the antibody fragment is selected from a Fab, F(ab′)2, Fv, Fd, and a scFv.

5. The method of claim 1 , wherein the antibody is an IgG1.

6. The method of claim 1 , which promotes T cell-mediated killing of virally infected cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2019
From: NOELLE, RANDOLPH J.; LU, LI-FAN; QUEZADA, SERGIO; GONDEK, DAVID
To: TRUSTEES OF DARTMOUTH COLLEGE
Reel/Frame 051123/0724 →
CONFIRMATORY LICENSE Recorded Jan 23, 2012
From: DARTMOUTH COLLEGE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027579/0670 →
Continuity (3)
Division 11912397
Provisional Application 60674567 · Apr 25, 2005
Related Publication 20120195894A1 · Aug 2, 2012